Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure that has historically been underdiagnosed due to nonspecific clinical presentation and limited awareness. Advances in non-invasive diagnostic modalities have transformed the identification of ATTR-CM, allowing accurate diagnosis without routine reliance on endomyocardial biopsy and enabling earlier-stage disease detection. These developments have coincided with a rapidly evolving therapeutic landscape, marked by the introduction of disease-modifying treatments that directly target transthyretin stability or production rather than providing solely supportive care.
